Usefulness of a run-in period to reduce drop-outs in a randomized controlled trial of a behavioral intervention

Contemporary Clinical Trials

Volumn 29, Issue 5, 2008, Pages 705-710

  Ulmer, Michelle ^a   Robinaugh, Donald ^a   Friedberg, Jennifer P ^a,b   Lipsitz, Stuart R ^c   Natarajan, Sundar ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Behavioral intervention; Generalizability; Hypertension; Randomized controlled trial

Indexed keywords

ADULT; AGED; ARTICLE; BEHAVIOR MODIFICATION; BEHAVIOR THERAPY; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INFORMED CONSENT; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PATIENT COUNSELING; PATIENT PARTICIPATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TELECONSULTATION;

ADULT; AGED; AGED, 80 AND OVER; BEHAVIOR THERAPY; BLOOD PRESSURE; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TELEPHONE;

EID: 49749083818     PISSN: 15517144     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cct.2008.04.005     Document Type: Article

References (28)

1. Hartling L., McAlister F.A., Rowe B.H., Ezekowitz J., Friesen C., and Klassen T.P. Challenges in systematic reviews of therapeutic devices and procedures. Ann Intern Med 142 12 Pt 2 (2005) 1100-1111
2. Berger V.W., Rezvani A., and Makarewicz V.A. Direct effect on validity of response run-in selection in clinical trials. Control Clin Trials 24 2 (2003) 156-166
3. Shumaker S.A., Dugan E., and Bowen D.J. Enhancing adherence in randomized controlled clinical trials. Control Clin Trials 21 5 Suppl (2000) 226S-232S
4. Blackwelder W.C., Hastings B.K., Lee M.L.F., and Deloria M.A. Value of a run-in period in a drug trial during pregnancy. Control Clin Trials 11 3 (1990) 187-198
5. Freedman L.S. The effect of partial noncompliance on the power of a clinical trial. Control Clin Trials 11 3 (1990) 157-168
6. Lachin J.M. Statistical considerations in the intent-to-treat principle. Control Clin Trials 21 3 (2000) 167-189
7. Little R.J., and Rubin D.B. Statistical analysis with missing data. 2nd ed (2002), John Wiley & Sons, New York xv+381
8. Knipschild P., Leffers P., and Feinstein A.R. The qualification period. J Clin Epidemiol 44 6 (1991) 461-464
9. Hallstrom A.P., Verter J., and Friedman L. Randomizing responders. Cardiac Arrhythmia Suppression Trial (CAST) investigators. Control Clin Trials 12 4 (1991) 486-503
10. Stewart W.C., Jackson A.L., and Jenkins J.N. Dropout rates for intent-to-treat and per protocol analyses. Am J Ophthalmol 137 4 (2004) 639-645
11. Wirth A., and Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286 11 (2001) 1331-1339
12. Pablos-Mendez A., Barr R.G., and Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 279 3 (1998) 222-225
13. Kopec J.A., Abrahamowicz M., and Esdaile J.M. Randomized discontinuation trials: utility and efficiency. J Clin Epidemiol 46 9 (1993) 959-971
14. Perez V., Gilaberte I., Faries D., Alvarez E., and Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349 9065 (1997) 1594-1597
15. Kiel D.P., Magaziner J., Zimmerman S., Ball L., Barton B.A., Brown K.M., et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA 298 4 (2007) 413-422
16. Elam M.B., Hunninghake D.B., Davis K.B., Garg R., Johnson C., Egan D., et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA 284 10 (2000) 1263-1270
17. Sesso H.D., Gaziano J.M., VanDenburgh M., Hennekens C.H., Glynn R.J., and Buring J.E. Comparison of baseline characteristics and mortality experience of participants and nonparticipants in a randomized clinical trial: the Physicians' Health Study. Control Clin Trials 23 6 (2002) 686-702
18. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L.Jr., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289 19 (2003) 2560-2572
19. Prochaska J.O., and DiClemente C.C. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol 51 3 (1983) 390-395
20. Walline J.J., Jones L.A., Mutti D.O., and Zadnik K. Use of a run-in period to decrease loss to follow-up in the Contact Lens and Myopia Progression (CLAMP) study. Control Clin Trials 24 6 (2003) 711-718
21. van der Ven N.C., Hogenelst M.H., Tromp-Wever A.M., Twisk J.W., van der Ploeg H.M., Heine R.J., et al. Short-term effects of cognitive behavioural group training (CBGT) in adult Type 1 diabetes patients in prolonged poor glycaemic control. A randomized controlled trial. Diabet Med 22 11 (2005) 1619-1623
22. Renaud J., Brent D.A., Baugher M., Birmaher B., Kolko D.J., and Bridge J. Rapid response to psychosocial treatment for adolescent depression: a two-year follow-up. J Am Acad Child Adolesc Psych 37 11 (1998) 1184-1190
23. Brittain E., and Wittes J. The run-in period in clinical trials. The effect of misclassification on efficiency. Control Clin Trials 11 5 (1990) 327-338
24. Davis C.E., Applegate W.B., Gordon D.J., Curtis R.C., and McCormick M. An empirical evaluation of the placebo run-in. Control Clin Trials 16 1 (1995) 41-50
25. Hudmon K.S., Chamberlain R.M., and Frankowski R.F. Outcomes of a placebo run-in period in a head and neck cancer chemoprevention trial. Control Clin Trials 18 3 (1997) 228-240
26. Reimherr F.W., Ward M.F., and Byerley W.F. The introductory placebo washout: a retrospective evaluation. Psychiatry Res 30 2 (1989) 191-199
27. Greenspan S.L., Resnick N.M., and Parker R.A. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial. JAMA 289 19 (2003) 2525-2533
28. Lang J.M., Buring J.E., Rosner B., Cook N., and Hennekens C.H. Estimating the effect of the run-in on the power of the Physicians' Health Study. Stat Med 10 10 (1991) 1585-1593